LOXAPINE SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Loxapine Succinate patents expire, and when can generic versions of Loxapine Succinate launch?
Loxapine Succinate is a drug marketed by Elite Labs Inc, Lannett Co Inc, Rising, and Watson Labs. and is included in seven NDAs.
The generic ingredient in LOXAPINE SUCCINATE is loxapine succinate. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loxapine succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Loxapine Succinate
A generic version of LOXAPINE SUCCINATE was approved as loxapine succinate by WATSON LABS on June 15th, 1988.
Summary for LOXAPINE SUCCINATE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 2 |
Patent Applications: | 2,018 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LOXAPINE SUCCINATE |
DailyMed Link: | LOXAPINE SUCCINATE at DailyMed |
Recent Clinical Trials for LOXAPINE SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Witten/Herdecke | Phase 2 |
Mylan Pharmaceuticals | Phase 1 |